Loading stock data…
$1.39-2.56 (-64.81%)
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Aardvark Therapeutics, Inc. in the Healthcare sector is trading at $1.39 with a market capitalization of $114M. Wall Street consensus targets $12.57 (7 analysts), implying a +804.4% move over the next 12 months. The stock is currently near its 52-week low of $1.39, remaining 79.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$15.08M↑ | -$22.46M↓ | -$18.70M↓ | -$17.70M↓ | -$15.85M |
| Net Income | -$14.39M↑ | -$21.59M↓ | -$17.60M↓ | -$16.32M↓ | -$14.37M |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated i...